Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis

Main Article Content

Alan Menter
Andrew Blauvelt
Bruce Strober
Matthew Colombo
Renata Kisa
Sudeep Kundu
Subhashis Banerjee
Craig Leonardi

Keywords

Psoriasis, Tyrosine Kinase 2 Inhibitor, TYK2 Inhibitor, Oral, Quality of Life

Abstract

Abstract not available.

References

1. Puig L et al. Acta Derm Venereol. 2019;99:971-7.

2. Spuls PI et al. J Invest Dermatol. 2010;130:933-43.

3. Armstrong AW et al. J Am Acad Dermatol. 2017;76:290-8.

4. Burke JR et al. Sci Transl Med. 2019;11:1-16.

5. Papp K et al. N Engl J Med. 2018;379:1313-21.